Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Esther Natalie Oliva, MD, Valeria Santini, MD, Gina Zini, Giuseppe A Palumbo, Antonella Poloni, MD, Agostino Cortelezzi, MD, Maria Teresa Voso, Alfredo Molteni, Grazia Sanpaolo, MD, Antonio Marino, Filippo Rodà, MD, Caterina Alati, Francesca Ronco, Francesco Di Raimondo, Pietro Leoni, MD, Giuliana Alimena, Silvia Finotto, Roberto Latagliata, MD, Francesco Nobile, MD

Blood (2012) 120 (21): 923.

https://doi.org/10.1182/blood.V120.21.923.923

Published: 2012

Journal Articles

Familial Chronic Myeloproliferative Neoplasms

Caterina Alati, Bruno Martino, Antonio Marino, Francesca Ronco, Manuela Priolo, Francesco Nobile, MD

Blood (2010) 116 (21): 3078.

https://doi.org/10.1182/blood.V116.21.3078.3078

Published: 2010

Journal Articles

Gene Expression Profile (GEP) Analysis as a Tool to Control the Efficacy Dasatinib Treatment in Relapsed Imatinib-Resistant CML Patients Previously Undergone to Allogeneic Stem Cell Transplantation. Preliminary Data of a Single Institution

Bruno Martino, MD, Maria Cuzzola, Carmela Rigolino, Domenica Ielo, Antonio Marino, MD, Francesco Nobile, Pasquale Iacopino, MD

Blood (2008) 112 (11): 4260.

https://doi.org/10.1182/blood.V112.11.4260.4260

Published: 2008

Journal Articles

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Blood (2008) 112 (11): 485.

https://doi.org/10.1182/blood.V112.11.485.485

Published: 2008

Journal Articles

Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Bruno Martino, Giovanna Rege Cambrin, Antonella Gozzini, Fabio Stagno, Massimo Breccia, Giorgina Specchia, Ester Orlandi, Ester Pungolino, Franca Falzetti, Sara Galimberti, Carmen Fava, Antonio Marino, Francesco Nobile

Blood (2007) 110 (11): 4564.

https://doi.org/10.1182/blood.V110.11.4564.4564

Published: 2007

Journal Articles

Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.

Iolanda Vincelli, MD, Esther N. Oliva, MD, Roberto Latagliata, MD, Giorgina Specchia, MD, Giuliana Alimena, MD, Massimo Breccia, MD, Caterina Alati, MD, Ida Carmosino, MD, Grazia Iaria, MD, Antonio Marino, MD, Natale Ranieri, MD, Vincenzo Liso, MD, Francesca Ronco, MD, Bruno Martino, MD, Francesco Nobile, MD

Blood (2006) 108 (11): 3595.

https://doi.org/10.1182/blood.V108.11.3595.3595

Published: 2006

NARROW

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Familial Chronic Myeloproliferative Neoplasms

Gene Expression Profile (GEP) Analysis as a Tool to Control the Efficacy Dasatinib Treatment in Relapsed Imatinib-Resistant CML Patients Previously Undergone to Allogeneic Stem Cell Transplantation. Preliminary Data of a Single Institution

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Familial Chronic Myeloproliferative Neoplasms

Gene Expression Profile (GEP) Analysis as a Tool to Control the Efficacy Dasatinib Treatment in Relapsed Imatinib-Resistant CML Patients Previously Undergone to Allogeneic Stem Cell Transplantation. Preliminary Data of a Single Institution

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only